Bausch Health Companies Inc Bhc Ceo Joe Papa On Q2 2018 Results Earnings Call Transcript | Latest News RSS feed

Bausch Health Companies Inc Bhc Ceo Joe Papa On Q2 2018 Results Earnings Call Transcript - Latest News


Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at Cantor Global Healthcare Conference 2018 (Transcript)

Bausch Health Companies Inc. (NYSE:BHC) Company Conference Presentation October 1, 2018 3:30 PM ET Executives Joe Papa - Chairman and CEO Analysts ... in the call and maybe a little bit more since I ... read more

Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018

Shares of Bausch Health Companies (formerly known as Valeant Pharmaceuticals) (NYSE: BHC) (TSX: VRX) have acquitted themselves admirably at the mid-way point in 2018 by gaining ... is that Bausch's ... read more

7 Rising Healthcare Stocks to Consider

Previously beaten up and left to fall to the single-digits, Bausch Health Companies (NYSE ... note the insider buying activity with BHC stock. Director Richard De Schutter bought 125,000 shares at $23 ... read more

Looking for another news?


Will Valeant Pharmaceuticals' Turnaround Fizzle with Its Q4 Results?

When Valeant Pharmaceuticals (NYSE:BHC) reported its third-quarter results in November, CEO Joe ... Valeant in 2018. However, the psoriasis market is crowded, so Siliq might not be the success story ... read more


Valeant Is Growing Once More

It is changing its name to Bausch Health Companies Inc ... from the earnings call: Beginning in late 2016, Joe took steps to globalize the lens business and to put in place leadership to drive this ... read more

Bausch Health Companies' Organic Growth Streak Continues in the Third Quarter

Bausch Health Companies Inc. (NYSE: BHC) got off to a pretty good start under its new name when the company reported its second-quarter results in August ... guidance of $3.2 billion to $3.35 billion. ... read more

This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August

On the surface, Valeant Pharmaceuticals ... company is on track to meet its $5 billion aggregate debt-reduction target by February 2018. So, what's the issue? Look no further than commentary from CEO ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us